An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT02576509 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

743

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Sorafenib

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]